SecurityNVS / Novartis AG
InstitutionVident Investment Advisory, LLC
Shares33,164
Value $ 2,505,000
Related 66989HAB4 / Novartis Capital Corp 1.9% 04/24/13
66989HAE8 / Novartis Capital Corp 2.4% 09/21/2022
66989HAC2 / Novartis Capital Corp. 2.9% 04/24/15
66989HAF5 / Novartis Capital Corp 3.7% 09/21/2042
66989HAA6 / Novartis Capital Corp. 4.125% 02/10/14
66989HAD0 / Novartis Capital Corp 4.4% 04/24/2020
66989GAA8 / Novartis Securities Investment Guaranteed Notes 5.125% 02/10/19

Vident Investment Advisory, LLC reports 58.67% increase in ownership of NVS / Novartis AG

August 14, 2018 - Vident Investment Advisory, LLC has filed a 13F-HR form disclosing ownership of 33,164 shares of Novartis AG (NYSE:NVS) with total holdings valued at $2,505,000 USD as of June 30, 2018. Vident Investment Advisory, LLC had filed a previous 13F-HR on May 14, 2018 disclosing 20,901 shares of Novartis AG at a value of $1,699,000 USD. This represents a change in shares of 58.67 percent and a change in value of 47.44 percent during the quarter.

Other investors with positions similar to Vident Investment Advisory, LLC include HPM Partners LLC, Banco Santander, S.A., Woodmont Investment Counsel Llc, MUFG Americas Holdings Corp, Frontier Wealth Management LLC, and Bokf, Na.

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR NOVARTIS A G SPONSORED ADR 66987V109 78.41 33,164 58.67 2,505 47.44 962 -156 -9.16
2018-03-31 13F-HR NOVARTIS A G SPONSORED ADR 66987V109 82.62 20,901 41.40 1,699 36.91 506 -48 -3.84
2017-12-31 13F-HR NOVARTIS A G SPONSORED ADR 66987V109 84.91 14,781 2.59 1,241 0.32 32 -28 -2.24
2017-09-30 13F-HR NOVARTIS A G SPONSORED ADR 66987V109 84.65 14,408 3.12 1,237 6.09 37 34 2.92
2017-06-30 13F-HR NOVARTIS A G SPONSORED ADR 66987V109 78.85 13,972 12.16 1,166 26.05 119 122 13.14
2017-03-31 13F-HR NOVARTIS A G SPONSORED ADR 66987V109 73.53 12,457 19.03 925 21.39 146 17 2.17
2016-12-31 13F-HR/A-1 NOVARTIS A G SPONSORED ADR 66987V109 75.91 10,465 18.80 762 9.48 126 -60 -8.58
2016-12-31 13F-HR NOVARTIS A G SPONSORED ADR 66987V109 10,465 762
2016-09-30 13F-HR NOVARTIS A G SPONSORED ADR 66987V109 80.73 8,809 -0.50 696 -4.66 -4 -30 -4.17
2016-06-30 13F-HR NOVARTIS A G SPONSORED ADR 66987V109 77.44 8,853 -53.06 730 -46.56 -775 139 10.17
2016-03-31 13F-HR/A-1 NOVARTIS A G SPONSORED ADR 66987V109 79.24 18,860 109.39 1,366 76.26 781 -190 -24.48
2016-03-31 13F-HR NOVARTIS A G SPONSORED ADR 66987V109 1,366,218 18
2015-12-31 13F-HR NOVARTIS A G SPONSORED ADR 66987V109 9,007 0.00 775 775 0
2015-09-30 13F-HR NOVARTIS A G SPONSORED ADR 66987V109 0 -100.00 0 -100.00 0 0
2015-06-30 13F-HR NOVARTIS A G SPONSORED ADR 66987V109 98.46 18,190 31.55 1,789 31.25 430 -4 -0.26
2015-03-31 13F-HR NOVARTIS A G SPONSORED ADR 66987V109 13,827 1,363

Related SEC Filings

Novartis Form SC 13D (Acquisition of More Than 5% of Shares)

2016-02-13 sec.gov
    UNITED STATES     SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549           SCHEDULE 13D     Under the Securities Exchange Act of 1934 (Amendment No.     )*   Arrowhead Research Corporation (Name of Issuer)   COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities)   042797209 (CUSIP Number)   Scott Brown General Counsel Novartis Institutes for BioMedical Research, Inc.

Novartis Form SC 13D/A (Acquisition of More Than 5% of Shares)

2015-12-12 sec.gov
    UNITED STATES     SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549         SCHEDULE 13D   Under the Securities Exchange Act of 1934 (Amendment No. 2)*     Momenta Pharmaceuticals, Inc. (Name of Issuer)     COMMON STOCK, Par Value $.0001 Per Share (Title of Class of Securities)     60877T100 (CUSIP Number)     Dr. Christian Rehm Novartis AG Lichstrasse 35 CH 4056 Basel, Switzerland +41 61 324 1111   With a copy to:   G.

Novartis Form SC 13D/A (Activist Acquisition of More Than 5% of Shares)

2014-08-12 sec.gov
    UNITED STATES     SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549           SCHEDULE 13D     Under the Securities Exchange Act of 1934 (Amendment No. 11)*   Idenix Pharmaceuticals, Inc. (Name of Issuer)   Common Stock (Title of Class of Securities)   45166R204 (CUSIP Number)   Rebecca Weston Novartis Pharma AG Lichtstrasse 35 CH-4056 Basel, Switzerland +41 61 324 7015   With a copy to:   Peter Harwich Allen & Overy LLP 1221 Avenue of the Americas New York, New York 10020 +1 212 (0-1)

Novartis Form SC 13D/A (Activist Acquisition of More Than 5% of Shares)

2014-07-29 sec.gov
    UNITED STATES     SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549           SCHEDULE 13D     Under the Securities Exchange Act of 1934 (Amendment No. 10)*   Idenix Pharmaceuticals, Inc. (Name of Issuer)   Common Stock (Title of Class of Securities)   45166R204 (CUSIP Number)   Rebecca Weston Novartis Pharma AG Lichtstrasse 35 CH-4056 Basel, Switzerland +41 61 324 7015   With a copy to:   Peter Harwich Allen & Overy LLP 1221 Avenue of the Americas New York, New York 10020 +1 212

Related News Stories

Biotech Stocks Bloodied But Can Now Drive M&A

2018-10-19 seekingalpha
The biotech stocks plunge along with the broader market, as the smallcap and midcap biotech stocks retreat -17%. (41-2)

Assembly Biosciences: A Horseman Of The HBV Core-Pocalypse?

2018-10-19 seekingalpha
Assembly Biosciences is shaping up to be a major player in the future of Hepatitis B therapeutics. (14-0)

Novartis' (NVS) CEO Vas Narasimhan on Q3 2018 Results - Earnings Call Transcript

2018-10-19 seekingalpha
Thank you very much and good morning, and good afternoon, everybody. Before we start, I just wanted to read to you the safe harbor statements. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. (1-1)

Biotech Analysis Central Pharma News: Regeneron's Results, BMY's Failure, Novartis' FDA Rejection

2018-10-19 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. (3-0)

Are Endocyte Investors Getting Enough in the Buyout?

2018-10-18 247wallst
Endocyte Inc. (NASDAQ: ECYT) shares were up sharply on Thursday after it was announced that Novartis A.G. (NYSE: NVS) would acquire the company. The transaction was unanimously approved by the board of directors of Endocyte, but it is still subject to Endocyte stockholder and regulatory approvals. (1-1)



CUSIP: 66987V109